Synedica Laboratories specialise in manufacturing the world’s most advanced appetite suppressant injection pen kits for research and development.
Explore the full range of Synedica weight loss solutions
Frequently Asked Questions
Retatrutide is a state-of-the-art innovative drug that acts as a triple agonist of GLP-1, GIP and Glucagon receptors, representing a significant advance in the treatment of obesity and weight control.
Unlike conventional drugs, Retatrutide works simultaneously on three metabolic pathways, enhancing weight loss in a more efficient and sustainable way.
Clinical studies have shown impressive results, with patients achieving up to 24% body weight reduction in 48 weeks of treatment.
Guarantees that make a difference in your treatment
Unlike conventional drugs,Retatrutideworks simultaneously on three metabolic pathways, enhancing weight loss more efficiently and sustainably, with studies showing up to 24% body weight reduction.
Frequently Asked Questions
Synedica Tirzepatide 40mg is a weight management treatment designed by Synedica to support individuals living with obesity or weight-related health conditions. It belongs to the class of medicines known as GLP-1 receptor agonists, which help regulate appetite, control cravings, and improve metabolic health.
Tirzepatide 40mg is typically used in combination with a reduced-calorie diet and regular exercise for effective and long-term weight management.
Guarantees that make a difference in your treatment
Tirzepatide works by mimicking the natural hormone GLP-1 (glucagon-like peptide-1), which plays a vital role in controlling appetite and blood sugar levels. By stimulating GLP-1 receptors:
- Reduces hunger and promotes a feeling of fullness
- Helps control portion sizes and snacking
- Slows gastric emptying for prolonged satiety
- Supports sustainable weight loss and improved blood sugar control